Shared Decision Making With Clients Can Improve Treatment Engagement, Medication Adherence

This study focused on a specific tool called CommonGround, an offering on the My Collaborative Health Outcomes Information System (MyCHOIS), a web-based platform developed by the New York State Office of Mental Health (NYSOMH). Molly T. Finnerty, M.D., of NYSOMH and colleagues examined the effects of MyCHOIS-CommonGround on treatment engagement, and for patients with schizophrenia, adherence to antipsychotic medication regimens.Some 472 Medicaid patients completed shared decision-making reports using MyCHOIS-CommonGround, summarizing their symptoms, functioning, and concerns, with the help of peer staff. Later, during a medication appointment, the clinician and patient reviewed the report and worked together to develop a shared decision. Also studied were 944 similar Medicaid patients who did not use the program. Among participants, schizophrenia was the most prevalent diagnosis (40%), and about one-third of the patients had a comorbid substance use disorder.While there were no differences between the two groups at baseline, during the follow-up year, the MyCHOIS –CommonGround users had a higher level of ongoing engagement in outpatient mental health service compared with the control group (months with use of a service, 8.54 versus 6.95), the researchers wrote. Furthermore, at the one-year follow-up, there was a significant increase in ongoing treatment en gagement for the MyCHOIS–CommonGround users group and a significant decrease in engagement for the control gr...
Source: Psychiatr News - Category: Psychiatry Tags: antipsychotics CommonGround Molly T. Finnerty Psychiatric Services in Advance schizophrenia shared decision making substance use disorder treatment engagement Source Type: research

Related Links:

Conditions:   Cognitive Impairment Associated With Schizophrenia;   Schizophrenia Interventions:   Drug: BIIB104;   Other: Placebo Sponsor:   Biogen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: Sleep disturbances and increased inflammation, which were common in schizophrenia, were associated in persons with schizophrenia. Moreover, women with schizophrenia had worse sleep quality and inflammation than men. Further examination of the sleep-inflammation links, their contribution to clinical outcomes, and sex-specific factors is warranted. PMID: 30442531 [PubMed - as supplied by publisher]
Source: The American Journal of Geriatric Psychiatry - Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research
 Turkey. Stuffing. Families sitting down to dinner and…  arguing? For many people, Thanksgiving Day isn’t a day to be thankful, but a day to dread, especially for people with mental illness who feel judged by their families. In this episode, Gabe and Michelle talk about how things can go wrong during the holidays and share some of their best and worst moments during family gatherings. The show also includes practical advice that you can use and share with your loved ones.  Take a moment to relax and laugh this coming Thursday and – on behalf of all of us at A Bipolar, a Schizophrenic, and a...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: A Bipolar, A Schizophrenic, and a Podcast Family Holiday Coping Schizophrenia Source Type: blogs
Yash B. Joshi, Gregory A. Light
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
Conclusion: On the one hand, most DBH polymorphisms from the currently available loci showed no linkage to AD, PD or SCZ, indicating the lower possibility of these loci serving as genetic markers of the risks of diseases with neurodegenerative characteristics. On the other hand, the DBH rs2283123 and rs2007153 polymorphisms could have opposite effects on SCZ development in Caucasians and be more specific in Croatians, while the DBH rs1611131 minor variant might have a protective effect on AD risk in Caucasians; however, these results require further study.Cell Physiol Biochem 2018;51:411 –428
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
ConclusionOur results indicate significant sex differences in the obesity, BMI, BDNF levels, and their association in chronic patients with schizophrenia, showing a significant inverse correlation between BMI and BDNF levels only in female patients. Thus, sex needs to be considered when assessing the relationship between BDNF and metabolic syndromes in schizophrenia.
Source: Psychopharmacology - Category: Psychiatry Source Type: research
AbstractWe evaluated the effectiveness and acceptability of metacognitive interventions for mental disorders. We searched electronic databases and included randomized and non ‐randomized controlled trials comparing metacognitive interventions with other treatments in adults with mental disorders. Primary effectiveness and acceptability outcomes were symptom severity and dropout, respectively. We performed random‐effects meta‐analyses. We identified Metacognitive Tr aining (MCTrain), Metacognitive Therapy (MCTherap) and Metacognition Reflection and Insight Therapy (MERIT). We included 49 trials with 2,609 patients. In...
Source: Clinical Psychology - Category: Psychiatry & Psychology Authors: Tags: COMPREHENSIVE REVIEW Source Type: research
AbstractIntroductionThere is little evidence regarding the most effective timing of augmentation of antidepressants (AD) with antipsychotics (AP) in patients with major depressive disorder (MDD) who inadequately respond to first-line AD (inadequate responders). The study ’s objective was to understand the association between timing of augmentation of AD with AP and overall healthcare costs in inadequate responders.MethodsUsing the Truven Health MarketScan® Medicaid, Commercial, and Medicare Supplemental databases (7/1/09 –12/31/16), we identified adult inadequate responders if they had one of the following ...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
The 15q11.2 BP1-BP2 cytogenetic region has been associated with learning and motor delays, autism, and schizophrenia. This region includes a gene that codes for the cytoplasmic FMRP interacting protein 1 (CYFIP1). CYFIP1 gene product is involved in actin cytoskeletal dynamics and interacts with the fragile X mental retardation protein (FMRP). Absence of FMRP causes fragile X syndrome (FXS). Since abnormal white matter microstructure has been reported in both FXS and in psychiatric disorders, we looked at the impact of 15q11.2 BP1-BP2 dosage on white matter microstructure.
Source: Biological Psychiatry - Category: Psychiatry Authors: Tags: Archival Report Source Type: research
Treatment ‐refractory schizophrenia affects at least 30% of all patients with schizophrenia. Clozapine remains the gold standard treatment as the chances of response with another non clozapine medication are very low. However, initiating and then maintaining patients on clozapine can be a challenge due to a complex titration regimen, dose‐related side‐effects and the requirement for regular monitoring. In this article, Dr Sharma describes the successful addition of fluvoxamine to clozapine in a patient to achieve a therapeutic level of clozapine.
Source: Progress in Neurology and Psychiatry - Category: Neurology Authors: Tags: Case notes Source Type: research
More News: Computers | Medicaid | Medical Ethics | Men | Psychiatry | Schizophrenia | Study